FOSUN TOWARDS A BRIGHTER LIFE











Douyin(Tik Tok)

HONG KONG, CHINA

Address : Room 808, Icbc Tower, 3 Garden Road, Central Tel: +852 2509 3228

Fax: +852 2509 9028

SHANGHAI, CHINA

Address: Building SI, Bund Finance Center, No. 600, Zhongshan East 2nd Road, Huangpu District Tel: +86 21 2315 6666 Fax: +86 21 6130 3288 Postcode: 200010

BEIJING, CHINA

Address : Fosun International Center, No. 237, Chaoyang North Road, Chaoyang District, Beijing Tel: +86 10 59152299

LISBON, PORTUGAL


Address: Largo Do Chiado 8, 1249-125 Lisbon, Portugal Tel: +351 213 401 500

NEW YORK, USA

Address : 28 Liberty Street, 44th Floor, New York, NY 10005, USA Tel : +1 646 553 5892

LONDON, UK

Address : Units 18 & 19, Part First Floor, The Royal Exchange, London EC3V 3LN Email:londonoffice@fosun.com



FOSUN复星

Rooted in China, Creating a Global Happiness Ecosystem Fulfilling the Needs of One Billion Families Worldwide in Health, Happiness and Wealth

CONTENTS

02 About Fosun

Business Overview

22 Fosun's Strategy

36 Our Pursuit

FOSUN, TOWARDS A BRIGHTER LIFE

MISSION

Creating happier lives for families worldwide

VISION

Rooted in China, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of one billion families in Health, Happiness, and Wealth

VALUE

Self-improvement, Teamwork, Performance, and Contribution to Society

A GLOBAL INNOVATION-DRIVEN **CONSUMER GROUP**

ABOUT FOSUN

Fosun was founded in 1992. Our mission is to provide high-quality products and services for families around the world in Health, Happiness, Wealth, and Intelligent Manufacturing segments

Total Revenue

10-year Compound Growth 13%

175.39 billion

Total Assets

823.1 billion

Number of Employees

108,000

Forbes Global Ranking 2022

NO. 589

ESG Rating · AA MSCI A HSI **Global Operations** 35+ Countries and regions with revenue exceeding RMB100 million **R&D Investment** • 10.4 billion 1,771 Patents for inventions 10+ Global technology innovation centers **Number of C-end Customers** 464 million Cumulative operable members¹



^{*} Currency in RMB and data as of 31 December 2022 unless otherwise specified

¹ Operable members: Customers who have agreed to official member terms and conditions of the brand, have granted private personal information, including phone numbers, and are identifiable, reachable and traceable, are defined as registered members (i.e. operable members). From 2022 onwards, this statistic includes consumers in the Fosun Health ecosystem

ROOTED IN CHINA, DEVELOPING GLOBALLY

Over the past 30 years, Fosun has implemented the twin-driver strategy of "Profound Industry Operations + Industrial Investment" to strengthen its foothold in various industries. Through continuous innovation, Fosun has achieved rapid development by capitalizing on the opportunities and momentum of China and the world's economic development

Pramerica Fosun Life Insurance Peak Reinsurance

Starcastle Senior Living

Atlantis Sanva Foshan Fosun Chancheng Hospital Sisram Med

Gland Pharma

Privatization of Club Med

Thomas Cook

Silver Cross

Luz Saúde

Roc Oil

Wolverhampton Wanderers Babytree AHAVA

DJULA WEI

Shede Spirits

Lovelink (formerly known as Baihe Jiayuan)

Songhelou

Wolford

Fosun Tourism Group was listed on HKEX

Fosun United Health Insurance Dongjia APP

Shanghai Henlius was listed on HKEX

Yelanggujiu

Sergio Rossi Bankhaus Lampe Wansheng

Fosun was founded

with a capital of RMB 38,000

Fosun Pharma was listed on China's

2002 Yuyuan Inc. Fosun Pharma

Nanjing Iron & Steel

Sinopharm Group

2007

Hainan Mining Fosun International (00656.HK) was listed on HKEX

Henlius



1994

Forte









2011











LEADERSHIP





Executive Director Chairman of the Company

Aged 55, is an Executive Director and Chairman of the Company and the founder of the Group. As at the end of the Reporting Period, he has also been a director of both Fosun Holdings and Fosun International Holdings (the direct and indirect controlling shareholders of the Company, respectively), honorary chairman of The Zhejjang Chamber of Commerce, Shanghai, etc., Mr. Guo was honored, among others, the "China Democratic League Anti-COVID-19 Outstanding Individual", the "Anti-epidemic Action Award" at the "2020 Ram Charan Management Practice Awards" hosted by Harvard Business Review man of Listed Company Award" at the "Top 100 Hong Kong Listed Company" Award, co-organized by Tencent News and Finet Group Limited, and "Lifetime Achievement Award" at the 16th CNBC Asia Business Leaders Award Ceremony etc.. Mr. Guo received a bachelor's degree in philosophy in 1989 and a master's degree in business administration in 1999, both from



Wang Qunbin

Executive Director

Aged 53, is an Executive Director and Co-Chairman of the Company, and the founder of the Group. Mr. Wang was a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Sinopharm (listed on the Hong Kong Stock Exchange). Mr. Wang was awarded "Asia Pacific Outstanding Entrepreneur Awards" by Enterprise Asia and "Best Asian Corporate Director" at the Asian Excellence Recognition Awards by Corporate Governance Asia , etc., and was named one of "China' s 50 Top-performing Corporate Leaders" by Harvard Business Review. Mr. Wang received a bachelor's (Chinese version), the "Outstanding Business- degree in genetic engineering from Fudan University in 1991.

Aged 50, is an Executive Director and Co-CEO of the Company, Mr. Chen joined the Group in 1994 and as at the end of the Reporting Period, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Shanghai Henlius (listed on the Hong Kong Stock Exchange), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange), a director of Gland Pharma (listed on the BSE Limited and National Stock Exchange of India Limited) and various companies within the Group. Mr. Chen was a director of Dian Diagnostics Group Co., Ltd. (listed on the Growth Enterprise Market Board of the Shenzhen Stock Exchange) and Sanyuan Foods (listed on the SSE), a non-executive director of BabyTree (listed on the Hong Kong Stock Exchange) and a co-chairman of New Frontier Health Corporation (delisted from the NYSE in January 2022). As at been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, a tee of the Chinese People's Political Consultative University in 2019. Conference etc., Mr. Chen was awarded "Asia' s Best CEO" by Corporate Governance Asia, etc.. Mr. Chen received a bachelor's degree in genetics from Fudan University in 1993 and an

EMBA degree from China Europe International

Business School in 2005.

Chen Qiyu

Executive Director

Co-CEO of the Company

Aged 49, is an Executive Director and Co-CEO of the Company, Mr. Xu joined the Group in 1998. and as at the end of the Reporting Period, he Pharma (listed on the Hong Kong Stock Exchange and the SSE), an executive director and chairman of FTG (listed on the Hong Kong Stock Exchange), a director of Yuyuan (listed on the SSE), Shanghai Foyo Culture & Entertainment Co., Ltd. (delisted from the NEEQ in April 2021) and various companies within the Group Mr. Xu was a non independent director of Hainan Mining (listed on the SSE), a non-executive director and vice chairman of Zhaojin Mining Industry Co., Ltd. (listed on the Hong Kong Stock Exchange), and a director of Shanghai Resource Property Consulting Co., Ltd. (delisted from the NEEQ in December 2020). As at the end of the Reporting Period, Mr. Xu has been a deputy to the 15th Shanghai Municipal People's Congress the end of the Reporting Period, Mr. Chen has and the chairman of Shanghai International Fashion Federation, Mr. Xu was awarded "Asia' s Best CEO" by Corporate Governance Asia, the "Shanghai 4 May Youth Medal" and "Shanghai Top Ten Youth Business People" etc.. Mr. Xu received a master's degree in business adminis tration from the East China Normal University in member of the 14th Shanghai Standing Commit- 2002 and received an EMBA degree from Fudan





Executive Director Co-CEO of the Company



Gong Ping

Executive Director Executive President and CFO of the Company

Aged 47, is an Executive Director, Executive President and CFO of the Company. Mr. Gong joined the Group in 2011 and as at the end of the Reporting Period, he has also been a director of Yuyuan (listed on the SSE) and various companies within the Group. He used to serve as a senior assistant to president of the Group, the general manager of Corporate Development Department and the CEO of Fosun Hive. He was the chairman of PAREF (listed on the Euronext Paris), a non-executive director of Shanghai Zendai Property Limited (listed on the Hong Kong Stock Exchange) and Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE), and a director of Shanghai Bailian Group Co., Ltd. (listed on the SSE) and Resource Property (delisted from the NEEQ in December 2020). Prior to joining the Group, Mr. Gong worked at Pudong branch and the headquarters of Bank of Shanghai as well as the PRC headquarters of Standard Chartered Bank. Mr. Gong also served as a global strategist at the headquarters of Samsung Group in Korea, carrying out special assignments across various sectors including financial services, technology and real estate worldwide. As at the end of the Reporting Period, Mr. Gong has been a council member of Shanghai Association for Youth Entrepreneurship and Employment. Mr. Gong graduated from Fudan University in 1998 with a bachelor's degree in international finance, and then obtained his master's degree in finance from Fudan University in 2005. Mr. Gong also received his master's degree in business administration from International Institute for Management Development (IMD) in Lausanne, Switzerland in 2008.



Huang Zhen

Executive Director Executive President of the Company

Aged 51, is an Executive Director and Executive President of the Company, Mr. Huang joined the Group in 2017 and as at the end of the Reporting Period, he has also been the chairman of Yuyuan (listed on the SSE), the director of Shede Spirits (listed on the SSE), Resource Property (delisted from NEEQ in December 2020), Shanghai Bailian (listed on the SSE). Sanyuan Foods (listed on the SSE), FTG (listed on the Hong Kong Stock Exchange) and various companies within the Group. Mr. Huang was a non-executive director of Zhaojin Mining (listed on the Hong Kong Stock Exchange). Before joining the Group, Mr. Huang was the deputy general manager of Shanghai Jahwa United Co., Ltd., and the general manager of Shanghai Herborist Cosmetics Co., Ltd., etc.. As at the end of the Reporting Period, Mr. Huang has been a nember of the 14th Shanghai Standing Committee of the Chinese People's Political Consultative Conference, a member of the 3rd Shanghai Huangpu District Standing Committee of the Chinese People's Political Consultative Conference, the chairman of Shanghai Huangpu District Federation of Industry and Commerce, the president of Shanghai Huangpu District Chamber of Commerce, the vice chairman of China Gold Association and Gems & Jewelry Trade Association of China, etc.. Mr. Huang was awarded "Top Ten Economic Figures in China's Circulation Industry" and "National Outstanding Commercial Entrepreneur", etc., Mr. Huang received a bachelor's degree in economics from Shanghai University of Finance and Economics in 1994 and an MBA degree from Webster Universi-




Pan Donghui

Executive Director Executive President and CHO of the Company

Aged 53, is an Executive Director, Executive President and chief human resources officer (CHO) of the Company. Mr. Pan joined the Group in 1994 and as at the end of the Reporting Period, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and FTG (listed on the Hong Kong Stock Exchange) and a director of Shanghai Fovo Culture & Entertainment Co., Ltd. (delisted from NEEQ in April 2021). Mr. Pan also served as a director of Shanghai Ganglian E-Commerce Holdings Co., Ltd. (listed on the Shenzhen Stock Exchange). Mr. Pan obtained a bachelor's degree in engineering from Shanghai Jiaotong University in China in 1991, and a master's degree in business administration from the University of Southern California in the United States in 2009.

GLOBAL BUSINESS FOOTPRINTS





BUSINESS

OVERVIEW

FOSUN FAMILY HOUSEHOLD CONSUMPTION ECOSYSTEM

MANUFACTURING

NISCO

海南矿业 HAINAN MINING

JEI/E捷威动力



翌耀科技

复睿智行



12 - 13

HFAITH

Transform the industry with technology to create healthier lives

Fosun adopts a global R&D + diversified innovation model (investment, incubation, BD, etc.) to create high-value innovative products in the fields of pharmaceutical, devices, and diagnosis

PHARMACEUTICALS

Fosun Pharma continues to increase investment in innovation and R&D to promote innovative transformation, and focuses on the three major business divisions of innovative medicines business, established medicines manufacturing and supply business and vaccines business

FOSUN PHARMA 恒星医药







MEDICAL DEVICES & DIAGNOSTICS


The medical devices & diagnostics segment has initially formed three business divisions focusing on medical cosmetology, health, and professional medical care

FOSUN MEDTECH



10 10 0110







Medical Diagnostics: Integrate innovative diagnostic technologies to protect health for all





D2 20 D2


Comprehensively promoted the operation integration of the diagnostic sector and established six major R&D & production bases. The business mainly includes immunodiagnosis, biochemical diagnosis, microbial diagnosis, molecular diagnosis, and Point-Of-Care Testing (POCT)

In June 2022, the F-C800p fully automated biochemical analyzer was approved for registration. After being connected with F-i3000, Fosun Diagnostics' FCi biochemical and immunological pipeline was formed to fully meet the testing needs of clinical departments

HEALTHCARE SERVICES

Accelerate online and offline integration and service network construction, and build a one-stop active health management model (FHMO) that integrates medicine and healthcare throughout the treatment course













DSUN PHARN

Over 30%

Revenue contribution of new and sub-new products

Over 260

Pipeline projects on innovation drugs, biosimilars, generic drugs, and consistency evaluation items

The world's first PD-1 inhibitor approved for the first-line treatment of small cell lung cancer (SCLC)

Han Si Zhuang 汉斯状®

Approved for three indications in China: MSI-H, sqNSCLC and ES-SCLC; SCLC indication was granted Orphan Drug Designation by the U.S. FDA and the European Commission (EC), the marketing authorization application (MAA) for the treatment of ES-SCLC in Europe was accepted by the European Medicines Agency (EMA)

More than 31 million doses of Comirnaty (mRNA COVID-19 vaccine)

Had been administered in Hong Kong SAR, Macau SAR and Taiwan region since its launch to end of February 2023

More than 300

da Vinci Surgical Systems installed in Chinese mainland, Hong Kong SAR and Macau SAR as of 31 December 2022

Over 700 million investment

Intuitive Fosun's Medical Robot Manufacturing and R&D Center started construction in Shanghai

The proportion of direct sales revenue on the medical beauty platform increased to 66%

Strengthened its global operational capabilities and added direct sales team in the U.K. and Dubai

Ranked 1st among China's non-public hospitals in terms of competitiveness for 5 consecutive years

Foshan Fosun Chancheng Hospital passed the Joint Commission International (JCI) accreditation with high score

RMB 5.89 billion

Fosun Pharma's R&D investment in 2022

249

Patents applied in the pharmaceuticals segment

China's first approved CAR-T cell therapy

Yi Kai Da 奕凯达® (ejilunsai injection)

As of the end of January 2023, it had benefited more than 300 patients with relapsed or refractory large B-cell lymphoma; the indication for second-line treatment was accepted in October 2022 and has been included in the list of priority review products

Azvudine tablets

Fully commercialized in China and included in the National Medical Insurance Drug Catalogue 2022; 6.74 million bottles delivered as of the end of 2022

More than 10 million

Surgeries operated by the da Vinci Surgical System

Launched 3 new products on the medical beauty platform

- 1) Alma Ted™, an Ultrasound-based treatment for hair loss
- 2) Professional Injectable Fillers Skincare Solution™
- 3) LMNT one™, a home-use beauty device

10 Internet hospital licenses

Has been integrating offline medical institutions and Internet medical platforms, and establishing online medical and healthcare services since 2021

6,333 beds¹

In member hospitals

1 It refers to the number of beds in member hospitals as of the end of 2022

12 major specialty alliances

Emphasizes the construction of disciplines with the establishment of specialty alliances including obstetrics and gynecology, cardiology, orthopedics. The team of leading experts in various specialties including urology, orthopedics, nephrology, and rehabilitation have made significant progress

HAPPINESS

Develop contents, models and products for families to link online platforms and offline scenarios

YUYUAN

As one of the flagship platforms of Fosun's Happiness segment, Yuyuan takes oriental lifestyle aesthetics as the key strategy to promote Chinese culture to the world, creating happier lives for families worldwide

Jewelry and Fashion









Food and Beverage







Liquor







Chinese Watches











Beauty & Health







FOSUN TOURISM GROUP

As a flagship platform of the Happiness segment, Fosun Tourism Group (FTG) is the world's largest leisure tourism resorts group, and is striving to create a new concept of "Better Holiday, Better Life", infusing evolving concepts of tourism and leisure into everyday living








LANVIN GROUP


A grand transformation. Lanvin Group has entered the new phase of global development











MORE HAPPINESS

Focusing on sports, e-sports, film and television, games and other content to create a diversified entertainment experience of Fosun





4,592

Points of sale

YUYUAN GARDEN LANTERN FESTIVAL

Inspired by Shanhaijing, also known as "the Classic of Mountains and Seas", the lantern festival attracted more than 4 million visitors; recommended by national media platforms and agencies stationed abroad

Time-honored brands with heritage; Bring brands to the global stage to reshape their future

Tong Han Chun Tang and AHAVA brands have developed rapidly

Operating nearly 70 resorts on six continents around the world

Plan to open 17 new resorts from 2023 to 2025; in 2022, Club Med recorded a business volume of RMB12.011 billion, an increase of 108% compared to 2021

Lanvin Group Gone Public

On 15 December 2022, Lanvin Group was listed on the New York Stock Exchange (NYSE) under the ticker symbol "LANV", becoming China's first global luxury goods group listed on the NYSE

Approx. 1,200

Lanvin Group's brands points of sale

8 championships and 3 runners-up

E-sports teams under Fosun Sports have accumulatively won 8 championships and 3 runners-up in various competitions, setting a record high

167 shops

Songhelou Suzhou-style noodle shop has 167 shops in 16 cities across the country

Two Chinese watchmakers

One Chinese chip

The High Quality Track of the Liquor Industry

Shede Spirits adheres to the "aged spirits strategy", the "multi-brand matrix strategy", the "brand rejuvenation strategy" and the "internationalization strategy"; exported to 25 countries and regions

Sanya's Tourism 3.0 Benchmark

In the first two months of 2023, Atlantis Sanya's business volume fully recovered and exceeded pre-pandemic levels, with an average room occupancy rate of 96%

+08

Lanvin Group's brands covering more than 80 countries and regions

Approx. 300

Lanvin Group's brands self-operated retail stores

One of the founding members of the English Football League

Fosun's Sports' Wolverhampton Wanderers F.C. in the Premier League has won 11 league titles, 4 FA Cups and 2 League Cups

WEALTH

Fosun actively expands into household finance, corporate finance, investment businesses and hive city globally and accelerates the development of innovative finance driven by technology. Fosun continuously strengthens the seamless docking capability of "Industry + Finance", capturing opportunities of global industrial integration

INSURANCE

Establish a global presence and adhere to innovative development and insurance ecosystem development











INVESTMENT MANAGEMENT

Industrial investment + financial investment as twin-driver to empower Health, Happiness, Wealth, and Intelligent Manufacturing in every stage of life





FOSUN CAPITAL 复星创富











HIVE

Introduce industries to cities to facilitate urban development, creating a global urban hive benchmark



IDÉRA











28 LIBERTY

RMB 60.3 billion

Premium

29.6%

Fosun Insurance Portugal's market share in Portugal in 2022

EUR 257 billion

Assets under HAL's service and management

EUR 1.86 billion

BCP's consolidated core net income

China's Top 6 Most Recognized Private Equity Firms by LPs in 2022

China's Top 11 Private Equity Firms in 2022

Fosun Capital

40+

Global Fosun Hive Cities

THE GRAND YUYUAN

A global fashion cultural zone showcasing the charm of oriental lifestyle aesthetics

RMB 160.7 billion

Investable assets

1 million+

Number of registered users of My Fidelidade APP

+12%

Growth in assets under HAL's service and management

+44.4%

BCP's YOY consolidated core net income growth

China's Top 100 Venture Capital Firms in 2022

Fosun RZ Capital

130+

Global Fosun Hive Projects

INTELLIGENT MANUFACTURING

Develop digital intelligence globally to empower industrial manufacturing
Fully implement the C2M model and leverage big data, artificial intelligence, IoT, and other emerging technologies to
promote intelligent manufacturing






FOCUSED STRATEGY TO EMPOWER THE SUSTAINABLE GROWTH: FOUR CORE COMPETENCIES TO DRIVE CORPORATE GROWTH



PROFOUND GLOBAL OPERATIONS



INNOVATION-DRIVEN

10.4 billion¹

Strengthen technology innovation capability (RMB)

1,771 Patents for

inventions

10+

Global technology innovation centers







LEADING CORE TECHNOLOGIES IN VARIOUS FIELDS

Innovative drug: focus on core therapeutic areas such as oncology, immunology, central nervous system, and chronic disease, and mainly strengthen core technology platforms such as small molecule, antibody/ADC, cell therapy, and RNA

Vaccine: platforms of bacterial vaccine + viral vaccine Device: three major platforms of medical cosmetology + respiratory health + professional medical care Research and application of oriental lifestyle aesthetics Construction of the 4D technology innovation system: five senses of consumers + technology innovation R&D + creative design + technology innovation digitalization Insurance: digital platform optimizes customer experience throughout the life cycle Intelligent travel: full-stack self-developed L2+ intelligent driving software and hardware solutions Industrial automation: leveraging digital twin, machine

New energy: from traditional energy to the upstream extension of new energy and new materials

to promote the industry's fully intelligence and

automation

vision and other technologies accumulated for many years in the industry, AIGC large models are introduced

INNOVATIVE TECHNOLOGY INNOVATION CENTERS IN VARIOUS FIELDS

Fosun Pharma Global R&D Center (national level) JEVE Technology Center (national level) Wanbang Biopharma Quality Department QC Lab² (CNAS certified)

Fosun Jinmei Global Technology Innovation Center² Fosun Pharma North America R&D Headquarters Shanghai Key Laboratory of Stem Cell Therapy Sichuan Engineering Technology Center for Intelligent Brewing of Baiju

Lanvin Group Design Center (Milan, Italy and the U.K.) Yuyuan Jewelry Creative House

Yuyuan Food & Culture Group Innovation Center Base Academician Enterprise Research Institute

Han Si Zhuang 汉斯状®



The world's first anti-PD-1 monoclonal antibody for first-line treatment of small cell lung cancer

Three indications have been approved in China (excluding Hong Kong SAR, Macau SAR and Taiwan region)

13-valent pneumococcal conjugate vaccine

FOSUN PHARMA 复星医药

Phase III clinical trial commenced in China (excluding Hong Kong SAR, Macau SAR and Taiwan region)

Shede Spirits



Tackling the technical solution of "upgrading and processing" base spirit with special new materials that maintain the characteristics of the aged base spirit"

Fusionride Technology



Launched a fusion sensing solution centered on high-performance 4D millimeter-wave radar

Hainan Mining



The 20,000-ton lithium hydroxide project (Phase I) invested by Hainan Mining has begun construction.

Hainan Mining is actively promoting the merger and acquisition

Yi Kai Da 奕凯达®



The first CAR-T cell therapy approved for launch in Chinese mainland

The indication for second-line treatment of adult large B-cell lymphoma was accepted in China (excluding Hong Kong SAR, Macau SAR and Taiwan region) and has been included in the list of priority review products

YOGAN



The first self-developed skin care brand for sensitive skin, YOGAN was launched

Fidelidade





The number of registered users of My Fidelidade APP exceeded 1 million, the proportion of medical reimbursement on the APP accounted for > 46%, and the proportion of digital auto insurance claims > 48%

Easun Technology



The self-developed new energy system was delivered to major overseas customers for the first time





² Application of CNAS (China National Accreditation Service for Conformity Assessment) certified laboratory is in progress

FC2M ECOSYSTEM



FOSUN HEALTH 复星健康

Membership Platform of Fosun's Ecosystem

Medical-grade, all-scenario, one-stop health ecosystem

SCENARIOS

INDUSTRIES

PLATFORMS

464 million

Cumulative number of operational members¹, an increase of 50.80 million members compared to 2021

6.9 billion (RMB)

Total value created by the Group's ecosystem²

133

Products with sales exceeding RMB100 million

22.58 million

Cumulative number of registered members of Fosun Health with 9.24 million new registered users in 2022

6.40 million

Cumulative number of registered members of Fosun Alliance, and the transaction conversion rate³ under accurate recommendation increased by 26%



FC2M

FOSUN/FAMILY

CLIENT


PRODUCTS AND SERVICES

1 Operational members: customers who have agreed to the official membership terms of the brand and granted privacy in any channel, and actively retained personal information including mobile phone numbers, to meet the needs of identifiable, reachable and traceable consumers are defined as registered members (i.e. operational members). From 2022 onwards, this statistic includes consumers in the Fosun Health ecosystem

2 It refers to the revenue contribution (before intercompany eliminations) directly or indirectly created by companies within the Fosun ecosystem for other companies within the ecosystem, including but not limited to cross-selling, product co-creation, membership contribution, membership sales transformation, and sales collaboration within the ecosystem, joint industrial investment, financing cooperation empowerment, industrial resource coordination, etc.

3 It refers to order conversion rate, facilitating order placement by sending marketing materials to users, as calculated by "number of users placing orders/number of users reached"

Overview of Fosun's ecosystem: intelligent connection, open coopetition, global empowerment, multiplier development Strategy of Fosun's ecosystem: make a concerted effort to strive for a common goal and share rewards to realize multiplier effect within the ecosystem



Building a solid foundation/capabilities for Fosun's ecosystem

Notes:

- 1. The companies are listed according to the consolidated financial statement of Fosun International
- 2. The companies are some of the strategic suppliers of Fosun
- 3. The companies are some of the strategic partners of Fosun

FES SYSTEM


FES

(Fosun Entrepreneurship / Ecosystem System)

The FES system is a continuously evolving management system that helps Fosun build core competitiveness of a longstanding enterprise and nurture talents with Fosun's entrepreneurship

The system provides Fosun with systematic methodology, tools, and processes to realize Fosun's global operations capabilities, globalization, technology innovation and smooth operation of Fosun's ecosystem


With the joint effort of all employees, a corporate culture of continuous improvement and continuous growth will be established, promoting the contribution of the "Power of Fosun" to the development of the whole society



Profound Industry Operations + Industrial Investment







100+
Professional tools

Practice

700+ Expert certifications annually

40+ Improvement activities annually 100+ FES best practice cases

FOCUS ON KEY TALENTS TO BUILD A TEAM WITH ENTREPRENEURIAL SPIRITS

Talents, the most valuable asset of Fosun
A robust team of talents determines the scalability of the company's future development





ELITE MANAGEMENT TEAM

150+ global partners
280+ industry partners,
400+ functional line partners
70+ innovation partners,
with regular rotation to deeply involve
in each project, sector, and region

GLOCAL

20+ overseas global partners coming from countries including Portugal, France, Germany, the U.K., Japan, India, and the U.S.

FOSUN'S TALENT DEVELOPMENT STRATEGY

Attract talents with
development, appraise talents
based on performance,
train talents through work,
and unite talents
with career opportunities

Build a multi-level and multi-dimensional partner system, incentivize partners, and adhere to a market-based, benefit-sharing entrepreneurial mechanism



FOSUN GLOBAL PARTNERS



Future Fosun global partners



MID-LEVEL ENTREPRENEURS



Future entrepreneur backups



FUTURE ENTREPRENEURS



High-potential talents



TECHNOLOGY INNOVATION TALENTS



Top scientists of Fosun ecosystem

Future Fosun Global Partners Backups

Build a 'pyramid-shaped' partner backup array, forming a competitive dynamic partnership management mechanism that allows talent appraisals at different levels according to their performance



REMARKABLE ESG ACHIEVEMENTS FOR A BRIGHTER LIFE



The only conglomerate in Greater China with a MSCI ESG rating of AA



Hang Seng Corporate Sustainability Index Series






S&P CSA ESG score outperformed 91% of global peers and was significantly above the industry average score



Selected as one of the constituents of FTSE4Good Index Series for the first time in 2022

ESG RATINGS CONTINUED TO IMPROVE IN 2022



FOSUN FOR GOOD



The Fosun Foundation was established in November 2012 as the main humanitarian arm of the Fosun Group and is a "5A Social Organization". Adhering to Fosun 's philosophy of "Self-improvement, Teamwork, Performance and Contribution to Society", Fosun Foundation insists on serving the society, the people and the nation. The coverage of the foundation includes disaster relief, healthcare, poverty alleviation, rural revitalization, education, community building, youth entrepreneurship and culture, art, etc., serving many countries and regions around the world

FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) is a non-profit organization launched and supported by the Fosun Group and Fosun Foundation. Its programs are characterized by contemporary, international, and highly interactive artworks. It has held a total of 26 art exhibitions and has attracted more than 1.62 million visitors since 2016

ASSIST AFRICA IN FIGHTING AGAINST MALARIA

Fosun Pharma supplied over 280 million artesunate injections to the international market, benefited over 56 million patients with severe malaria. Fosun Pharma has 30 antimalarial drugs were prequalified by the World Health Organization (WHO Prequalified Lists)

RURAL DOCTORS POVERTY ALLEVIATION PROGRAM

Up to now, the program has covered 73 counties in 16 provinces, municipalities, and autonomous regions

Sent a total of 226 staff to assist the counties Served approx. 24,000 rural doctors Benefited 3 million grassroots families

PROTECHTING GLOBAL YOUTH START-UP ACCELERATION PROGRAM

Received 896 applications from 40+ countries and regions since 2016

Won 3 international awards in recognition of its corporate social responsibility

33 closely cooperated start-up projects5 companies signed commercial contracts

TAI CHI ANTI-PARKINSON'S DISEASE, TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

The scientific research findings of Tai Chi as an adjuvant therapy for chronic diseases were published in international authoritative journals Organized 3,144 hours of Tai Chi charitable courses for 445 patients with Parkinson's disease since 2015

Organized 945.5 hours of online Tai Chi charitable courses, benefited 23,491 people since 2020

FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) aims to promote contemporary art and is committed to binding Chinese and international art and culture, and promote public awareness, understanding and engagement in global contemporary art. Fosun Foundation (Shanghai) continues to support local Chinese artists, providing a broad display platform for outstanding Chinese contemporary art works. Fosun Foundation (Shanghai) is located in the Bund Finance Center. Fosun Foundation (Chengdu) was opened in June 2022. Fosun Foundation (Shanghai) participates in, witnesses and leads the development of contemporary art and culture. As an art consultant, Fosun Foundation (Shanghai) has long showcased its collection of Chinese art works in global landmark buildings such as Liberty 28 in New York to promote global cultural and artistic exchanges

26 art exhibitions

1.62 million + visits

Committed to presenting international and Chinese contemporary art exhibitions and special exhibitions with rich content, including "Tadao Ando: Endeavors", "Yayoi Kusama: All About Love Speaks Forever", etc.

500 public education campaigns

39,120+ people participated in public education campaigns

Insist on organizing high-quality public education campaigns to help the public understand art and promote active participation in art-related events


370+ Fosun Foundation (Shanghai) Night and Aesthetic Journey

Organize diversified and comprehensive cross-brand activities to promote public awareness and public engagement in the latest contemporary art trends





Shanghai Municipal Administration of Culture and Tourism's "Civilization and Integrity, Art Appreciation" co-construction unit, Shanghai Public Welfare Base, Donghua University Aesthetic Education Practice Base



RURAL DOCTORS PROGRAM

Delivering hope to impoverished people in rural areas

The Rural Doctors Program is one of the key initiatives to realize the goal of common prosperity. In late 2017, under the guidance of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation, etc., initiated the Rural Doctors Poverty Alleviation Program ("Rural Doctors Program") to empower millions of rural doctors who are working in the frontlines, thereby accelerating the realization of Healthy China

6 years, 315

On-site workers

Provinces, cities, autonomous regions covered across the country

Key national poverty-stricken counties Administrative village

(including 13 counties in Three Regions and Three Prefectures in extreme poverty, which have all lifted out of poverty)

12,545

clinics assisted

23,956


Rural doctors served

3 million

Grass-root families benefited



The Rural Doctors Program was awarded the "China Charity Award" in September 2021 and the "Shanghai Charity Award" in December 2022



FIGHT AGAINST MALARIA IN AFRICA

Assisting in building a "malaria-free world"

280 million +

The number of vials of artesunate for injection (60mg) that Fosun Pharma supplied to the global market since 2005, according to incomplete sta-

56 million +

The number of patients with severe malaria that Artesun® (artesunate for injection) has saved

175 million

The number of children in high malaria transmission African countries benefited from SPAQ-CO *Disp, a malaria prevention drug for children which was prequalified by the World Health Organization

"We will join forces and work with anti-malaria experts as well as other parties to continue to carry out malaria education projects for the public and raise the public awareness of malaria prevention. We will also actively participate in public health improvement and make steady efforts to build a malaria-free world."

-- Guo Guangchang





TAI CHI ANTI-PARKINSON'S DISEASE, TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

Slow therapy for chronic disease to hold on to the good memories

Fosun Foundation cooperated with the Neurology Department of Ruijin Hospital to jointly launch "Tai Chi Anti-Parkinson's Disease" and "Tai Chi for Delaying Alzheimer's Disease"

TAI CHI ANTI-PARKINSON'S DISEASE

520

3.144 hours

Patients with Parkinson's disease served since 2015 Offline course

945.5 hours

23,491

Online course

Participants online

TAI CHI FOR DELAYING ALZHEIMER'S DISEASE


53

Patients with Alzheimer's


167.5 hours

Tai Chi charitable course organized (offline)

COMMUNITY TAI CHI VOLUNTEER INSTRUCTOR TRAINING







FIGHT AGAINST COVID-19: STAY TRUE TO OUR ORIGINAL ASPIRATION AND CONTRIBUTE TO SOCIETY

ASSIST THE GLOBAL FIGHT AGAINST COVID-19

(From 24 January 2020 to 3 April 2023)



SUPPORT CHINA'S FIGHT AGAINST COVID-19

Deployed nearly 3 million pieces of materials globally These strategic materials provide strong support for China's fight against COVID-19

When the COVID-19 pandemic broke out in early 2020 and China was in the most difficult time, Fosun leveraged its strong global resources deployment capability to source medical supplies from 23 countries

On 28 January 2020, the first batch of materials deployed by Fosun, 50,000 pieces of protective suits deployed from Germany, was delivered from Frankfurt to front-line medical staff in Wuhan and other front-line medical staff in just 5 days

Provided a total of more than 6.245 million pieces of materials in Shanghai's battle against COVID-19

As of 9 June 2022, anti-epidemic materials donated by Fosun Foundation and its partners to support the three projects, "Community Support", "Care for Elderly" and "Care for Children" in Shanghai's battle against COVID-19

Over the past three years in the fight against the pandemic, Fosun has continued to assist Wuhan, Sanya, Nanjing, Beijing, Xi'an, Zhengzhou, Shanghai, Hong Kong, Shenzhen, etc.

CONTRIBUTION TO SOCIETY

147 million pieces

Medical supplies deployed; such as COVID-19 nucleic acid testing kits, ventilators, face masks, protective suits, and gloves, for humanitarian relief support against COVID-19

18,000+

Ventilators put into use in the global flight against

Assisted 30+ countries

Fosun's self-developed COVID-19 nucleic acid detection kit has been certified by the China NMPA and the U.S. Food and Drug Administration (FDA), and obtained the European Union CE marking

20,000+

Oxygen concentrators provided to support India's fight against COVID-19

100,000 Pieces of KN95 face masks

"DRUG + VACCINE" TO ASSIST THE GLOBAL FIGHT AGAINST COVID-19

31 million doses of Comirnaty Had been administered in Hong Kong, Macau and Taiwan regions as of the end of February 2023

Following the rollout of the self-paid vaccination service of Comirnaty BNT162b2 original vaccine in Macau in 2022, the self-paid vaccination service for Comirnaty Bivalent Vaccine has been rolled out in Hong Kong and Macau in the first quarter of 2023, providing more vaccine options for people in need and helping to build a health protection barrier

Donated Azvudine tablets to 250 counties and cities across the country

In 2022, Azvudine tablets, China's first small molecule oral medication for COVID-19 jointly developed by Fosun Pharma and Henan Genuine Biotech, was included in the national Diagnosis and Treatment Protocol for COVID-19 and was covered by the national medical insurance scheme. At the beginning of 2023, the Fosun Foundation, together with Fosun Pharma and Genuine Biotech, launched the campaign "A Healthy Winter Action" to donate Azvudine tablets to 250 counties and cities across the country, helping the grassroots weather the epidemic during the New Year